Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
JAAA vs XBI: how they differ
JAAA and XBI hold 0% of their weight in the same names, and XBI returned more over the year.
Janus Henderson AAA CLO ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, JAAA and XBI hold 0% of their money in the same securities at the same weight.
| Only in JAAA | Only in XBI |
|---|---|
| KKR CLO 35 Ltd. 0.96% | Apogee Therapeutics Inc 1.49% |
| AB BSL CLO 1 Ltd. 0.88% | Moderna Inc 1.41% |
| Anchorage Capital CLO 16 Ltd. 0.82% | Twist Bioscience Corp 1.41% |
| Anchorage Capital CLO 17 Ltd. 0.80% | Oruka Therapeutics Inc 1.38% |
| Carlyle US CLO Ltd. 0.70% | Kymera Therapeutics Inc 1.36% |
| Carlyle US CLO Ltd. 0.67% | Viking Therapeutics Inc 1.31% |
| Regatta XIX Funding Ltd. 0.67% | Praxis Precision Medicines Inc 1.29% |
| Magnetite XXXII Ltd. 0.67% | Erasca Inc 1.27% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Apr 30, 2026 and Jun 30, 2026.
| JAAA Janus Henderson AAA CLO ETF | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | Janus | State Street |
| What it is | Henderson AAA CLO | SPDR S&P Biotech |
| Total return, 1 year | +4.9% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | −12.6 pts | +46.5 pts |
| Expense ratio | 0.20% | 0.35% |
| Already in the S&P 500 | 0.0% | 8.5% |
| Holdings | 600 | 150 |
JAAA in plain words
JAAA is an index equity fund tracking the Henderson AAA CLO. Over the year to Sep 11, 2026 it returned +4.9% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.20% a year. By its holdings filed for Apr 30, 2026, 0% of the fund by weight is stocks the S&P 500 also holds, across 600 positions, with the top ten at 7.5%.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, JAAA or XBI?
- In the year to Sep 12, 2026, with distributions reinvested, JAAA returned +4.9% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, JAAA or XBI?
- JAAA charges 0.20% a year and XBI charges 0.35%, so JAAA is cheaper. Fees come from each fund's prospectus.
- How much do JAAA and XBI overlap with the S&P 500?
- By their latest filed holdings, 0% of JAAA and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, JAAA against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/JAAA-XBI Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources